Innovative Regenerative Treatment with Nanofat Injection for Hypertensive Ischemic Leg Ulcer: A Case Report.

Early human evidence such as case series or small samples is exploring possible benefits.

• Level A · Stronger Clinical Evidence
• Level B · Emerging clinical evidence with positive signals
• Level C · Early human research exploring benefits
• Level D · Scientific groundwork from lab and animal studies
• Emerging · Emerging topic under active research

Abstract (original English)

Background Martorell's ulcer, also known as hypertensive ischemic leg ulcer (HYTILU) or Martorell hypertensive ischemic ulcer, presents significant therapeutic challenges. The regenerative potential of nanofat, derived from adipose tissue, offers a promising therapeutic option. Case presentation We describe a 75-year-old female patient with a chronic ischemic ulcer measuring 30.1 cm 2 and persisting for more than 5 years. The patient had longstanding hypertension, controlled with three antihypertensive medications, and type 2 diabetes mellitus with microangiopathy. A single injection of 5 mL nanofat, prepared using the Tonnard technique, was administered intradermally at the wound site. Within 3 months, the ulcer surface reduced by 70%, achieving complete healing at 6 months. Pain management was significantly improved, with the visual analog scale (VAS) decreasing from 8/10 to 0/10 within 7 days. Quality of life, assessed using the Nottingham Health Profile and SCAR-Q, showed remarkable improvement. No adverse events were noted. Conclusion This case shows how nanofat can promote quick healing, relieve pain, and improve quality of life in a chronic ischemic wound. It offers a safe, minimally invasive, and effective alternative to traditional treatments. More research is needed to validate these results.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.